Listed by the USPTO as VANN-OJUEKAIYE, KENDRA RAYCHELL
Tech Center 1600 • Art Units: 1600 1682 1693
This examiner grants 0% of resolved cases
VANN-OJUEKAIYE, KENDRA RAYCHELL has resolved 24 cases in technology center 1600 and art unit 1600. The allowance rate is 0.0%, and the median time to allowance is 1375 days. Interviews are associated with a 0.0% lift in the allowance rate. The limited resolved-case record calls for caution when drawing broad conclusions from these figures.
The Brigham and Women's Hospital Inc., Zoetis LLC, and Fujifilm Corporation are the listed leading companies. Kilpatrick Townsend & Stockton LLP - West Coast, Acuity Law Group, P.C., and BALLARD SPAHR LLP are the listed leading firms. The profile gives practitioners a focused view of the docket and indicates that the reported interview measure does not show an allowance-rate increase.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18357453 | EVALUATION METHOD FOR BISULFITE REAGENT AND GENETIC TEST METHOD | Final Rejection | FUJIFILM Corporation |
| 17806238 | METHODS AND COMPOSITIONS FOR CANCER DETECTION, CHARACTERIZATION OR MANAGEMENT IN COMPANION ANIMALS | Final Rejection | Zoetis Services LLC |
| 17413802 | TILED ASSAYS USING CRISPR-CAS BASED DETECTION | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 17634465 | IMMUNE SIGNATURES PREDICTIVE OF RESPONSE TO PD-1 BLOCKADE IN RICHTER'S TRANSFORMATION | Non-Final OA | DANA-FARBER CANCER INSTITUTE, INC. |
| 18568521 | USE OF CASD1 AS A BIOMARKER OF A CANCER EXPRESSING THE O-ACETYLATED-GD2 GANGLIOSIDE | Non-Final OA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE |
| 17908279 | PREDICTION OF RADIOTHERAPY RESPONSE FOR PROSTATE CANCER SUBJECT BASED ON T-CELL RECEPTOR SIGNALING GENES | Non-Final OA | KONINKLIJKE PHILIPS N.V. |
| 17561408 | MOLECULAR SUBTYPING, PROGNOSIS, AND TREATMENT OF BLADDER CANCER | Non-Final OA | The University of British Columbia |
| 17620077 | DIGITAL PCR MEASUREMENT METHOD AND MEASUREMENT DEVICE | Non-Final OA | Hitachi, Ltd. |
| 18296915 | TRANSMEMBRANE SENSORS AND MOLECULAR AMPLIFIERS FOR LYSIS-FREE DETECTION OF INTRACELLULAR TARGETS | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18037693 | ASSESSING RISK FOR COLORECTAL ADENOMA RECURRENCE BY NONINVASIVE MEANS | Final Rejection | The Chinese University of Hong Kong |
| 17486936 | METHODS FOR MODIFYING TRANSLATION | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 18006420 | COMPOSITIONS AND METHODS FOR ONE-STEP NUCLEIC ACID AMPLIFICATION AND DIAGNOSTIC METHODS BASED THEREON | Non-Final OA | King Abdullah University of Science and Technology |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy0.0% of resolved applications examined by Kendra Raychell Vann-Ojuekaiye were allowed (24 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +0.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Kendra Raychell Vann-Ojuekaiye took 1,375 days on average from filing to allowance.
Kendra Raychell Vann-Ojuekaiye examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
